WO2007065036A3 - Therapeutic conjugates and methods of using same - Google Patents
Therapeutic conjugates and methods of using same Download PDFInfo
- Publication number
- WO2007065036A3 WO2007065036A3 PCT/US2006/046459 US2006046459W WO2007065036A3 WO 2007065036 A3 WO2007065036 A3 WO 2007065036A3 US 2006046459 W US2006046459 W US 2006046459W WO 2007065036 A3 WO2007065036 A3 WO 2007065036A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- same
- compositions
- therapeutic conjugates
- gabapentin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides novel gabapentin-aminoadamantane derivative combinations (e.g. gabapentin-memantine) combinatorial compositions, methods of making the compositions, and methods for the treatment and prevention of neurological diseases, e.g., epilepsy, and neuropathic and chronic pain, using the compositions of the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74196205P | 2005-12-02 | 2005-12-02 | |
US60/741,962 | 2005-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007065036A2 WO2007065036A2 (en) | 2007-06-07 |
WO2007065036A3 true WO2007065036A3 (en) | 2008-07-31 |
Family
ID=37806190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/046459 WO2007065036A2 (en) | 2005-12-02 | 2006-12-04 | Therapeutic conjugates and methods of using same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007065036A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010507648A (en) | 2006-10-25 | 2010-03-11 | ラモット アット テル−アビブ ユニバーシティー リミテッド | Novel psychotropic drug with glutamic acid NMDA activity |
US8828665B2 (en) | 2007-02-16 | 2014-09-09 | Ark Diagnostics, Inc. | Compounds and methods for use in detecting gabapentin |
WO2010048423A1 (en) | 2008-10-24 | 2010-04-29 | Ark Diagnostics, Inc. | Levetiracetam immunoassays |
US9970929B2 (en) | 2013-01-18 | 2018-05-15 | Ark Diagnostics, Inc. | Voriconazole immunoassays |
EP2956444B1 (en) | 2013-02-13 | 2018-05-30 | ARK Diagnostics, Inc. | Posaconazole immunoassays |
CN118239847A (en) * | 2014-05-29 | 2024-06-25 | 广州喜鹊医药有限公司 | Preparation method of amantadine nitrate compound with neuroprotection effect |
WO2019104020A1 (en) * | 2017-11-22 | 2019-05-31 | Panorama Research, Inc. | Aminoadamantyl nitrate compounds and their use to treat cns disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142998A1 (en) * | 2000-10-06 | 2002-10-03 | Cundy Kenneth C. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
-
2006
- 2006-12-04 WO PCT/US2006/046459 patent/WO2007065036A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142998A1 (en) * | 2000-10-06 | 2002-10-03 | Cundy Kenneth C. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
Non-Patent Citations (9)
Title |
---|
BRYANS ET AL: "Identification of novel ligands for the Gabapentin binding site", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 41, 1 January 1998 (1998-01-01), pages 183818 - 45, XP002139354, ISSN: 0022-2623 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHI, WEI-GUO ET AL: "Design and synthesis of mutual prodrugs for relieving neuropathic pain (II)", XP002482875, retrieved from STN Database accession no. 2007:1408625 * |
HONG-JU Y ET AL: "Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 10, 17 May 2004 (2004-05-17), pages 2537 - 2541, XP004841234, ISSN: 0960-894X * |
OTAGIRI M ET AL: "Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimera drug", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 62, no. 1-2, 1 November 1999 (1999-11-01), pages 223 - 229, XP004363020, ISSN: 0168-3659 * |
SHARMA V ET AL: "Prodrugs and mutual prodrugs: Synthesis of some new pyrazolone and oxadiazole analogues of a few non-steroidal anti-inflammatory drugs", PHARMAZIE 20030201 DE, vol. 58, no. 2, 1 February 2003 (2003-02-01), pages 99 - 103, XP008092471, ISSN: 0031-7144 * |
SHI W ET AL: "DESIGN, SYNTHESIS, AND PRELIMINARY EVALUATION OF GABAPENTIN-PREGABALIN MUTUAL PRODRUGS IN RELIEVING NEUROPATHIC PAIN", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, vol. 338, no. 8, 1 January 2005 (2005-01-01), pages 358 - 364, XP008067446, ISSN: 0365-6233 * |
YOON MYUNG HA ET AL: "Antinociceptive interactions between intrathecal gabapentin and MK801 or NBQX in rat formalin test", JOURNAL OF KOREAN MEDICAL SCIENCE, vol. 20, no. 2, April 2005 (2005-04-01), pages 307 - 312, XP002482874, ISSN: 1011-8934 * |
ZHONGGUO XINYAO ZAZHI , 16(20), 1689-1692 CODEN: ZXZHA6; ISSN: 1003-3734, 2007 * |
ZOIDIS G ET AL: "The novel GABA adamantane derivative (AdGABA): design, synthesis, and activity relationship with gabapentin", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 13, no. 8, 15 April 2005 (2005-04-15), pages 2791 - 2798, XP004802818, ISSN: 0968-0896 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007065036A2 (en) | 2007-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006119295A3 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
WO2007127474A3 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
WO2005046603A3 (en) | Pyridine compounds | |
WO2007130383A3 (en) | Compositions and treatments using pyridazine compounds and secretases | |
WO2007002884A3 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
WO2007002361A3 (en) | 3-fluoro-piperidine t-type calcium channel antagonists | |
WO2006124748A3 (en) | Multicyclic compounds and methods of their use | |
WO2007022470A3 (en) | Methods and compositions for treating neurological disease | |
WO2007050793A3 (en) | Methods and compositions for the treatment of marfan syndrome and associated disorders | |
IL189622A0 (en) | Pharmaceutical compositions for the treatment of inner ear disorders | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
WO2007120729A3 (en) | Pyridyl amide t-type calcium channel antagonists | |
WO2005091853A3 (en) | Methods and compositions for treating il-13 related pathologies | |
WO2007064883A3 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2006131322A3 (en) | Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy | |
WO2006095029A3 (en) | Di-polymer protein conjugates and processes for their preparation | |
WO2007084684A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
WO2006058869A8 (en) | Substituted pteridines for treating inflammatory diseases | |
WO2007009120A3 (en) | Heterotetracyclic compounds as tpo mimetics | |
WO2007065036A3 (en) | Therapeutic conjugates and methods of using same | |
WO2007009007A3 (en) | Methods of treatment using hydroquinone ansamycins | |
WO2006058867A3 (en) | Substituted pteridines for the treatment of inflammatory diseases | |
WO2007022269A3 (en) | Compounds and compositions as tpo mimetics | |
WO2007051785A3 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
WO2007059341A3 (en) | Pyrazolothiazole protein kinase modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06839047 Country of ref document: EP Kind code of ref document: A2 |